Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Intellia Therapeutics is a leading clinical-stage biotech company specializing in CRISPR-based gene editing therapies. Its core focus is developing in vivo and ex vivo treatments for genetic diseases, including rare disorders like ATTR amyloidosis and hereditary angioedema, as well as cancer and autoimmune conditions. The company leverages proprietary technologies, strategic collaborations, and a broad IP portfolio to deliver potentially curative, precision medicines.
This description was generated via AI from an annual report. Updated about 1 year ago.